Hematology Clinical Trials | Clinical Trials GPS

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial GYN Plus

from

Ooltewah, TN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Joseph Hospital - Orange

from

Orange, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Desert Regional Medical Center

from

Palm Springs, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Midlands Community Hospital

from

Papillion, NE

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Keck Medical Center of USC Pasadena

from

Pasadena, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Singing River Hospital

from

Pascagoula, MS

OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Pekin, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Hospital West

from

Pembroke Pines, FL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Capital Health Medical Center-Hopewell

from

Pennington, NJ

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Illinois CancerCare-Peoria

from

Peoria, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

OSF Saint Francis Medical Center

from

Peoria, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Thomas Jefferson University Hospital

from

Philadelphia, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Huron Medical Center

from

Port Huron, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Providence Saint Vincent Medical Center

from

Portland, OR

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Southern Ohio Medical Center

from

Portsmouth, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Peninsula Cancer Center

from

Poulsbo, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Miriam Hospital

from

Providence, RI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Tacoma/Valley Radiation Oncology Centers-Puyallup

from

Puyallup, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Wheaton Franciscan Cancer Care - All Saints

from

Racine, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Duke Raleigh Hospital

from

Raleigh, NC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Northwest Hospital Center

from

Randallstown, MD

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente-Redwood City

from

Redwood City, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Radiation Oncology Associates

from

Reno, NV

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Valley Medical Center

from

Renton, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Mary's Hospital

from

Rhinelander, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Bon Secours Saint Mary's Hospital

from

Richmond, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Virginia Cancer Institute

from

Richmond, VA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente Riverside

from

Riverside, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

North Memorial Medical Health Center

from

Robbinsdale, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Harbin Clinic Medical Oncology and Clinical Research

from

Rome, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Sutter Roseville Medical Center

from

Roseville, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Cancer Care Associates PC

from

Royal Oak, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Helena Hospital

from

Saint Helena, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Norris Cotton Cancer Center-North

from

Saint Johnsbury, VT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Hospital Saint Louis

from

Saint Louis, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Carolina Oncology Associates PA

from

Salisbury, NC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Utah Cancer Specialists-Salt Lake City

from

Salt Lake City, UT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

LDS Hospital

from

Salt Lake City, UT

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente-San Diego Zion

from

San Diego, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente San Leandro

from

San Leandro, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente San Rafael

from

San Rafael, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kootenai Cancer Clinic

from

Sandpoint, ID

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente-Santa Rosa

from

Santa Rosa, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Memorial Health University Medical Center

from

Savannah, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Maine Center for Cancer Medicine-Scarborough

from

Scarborough, ME

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Swedish Medical Center-Ballard Campus

from

Seattle, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Minor and James Medical, PLLC

from

Seattle, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Swedish Medical Center-First Hill

from

Seattle, WA

Louisiana State University Health Sciences Center-Shreveport

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

from

Shreveport, LA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Dayton Physicians LLC-Wilson

from

Sidney, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Siouxland Regional Cancer Center

from

Sioux City, IA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Kaiser Permanente Cancer Treatment Center

from

South San Francisco, CA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Greenville Health System Cancer Institute-Spartanburg

from

Spartanburg, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Spartanburg Medical Center

from

Spartanburg, SC

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Evergreen Hematology and Oncology, PS

from

Spokane, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Rockwood Clinic Cancer Treatment Center-Valley

from

Spokane Valley, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Medical Center

from

Springfield, MA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Cox Medical Center South

from

Springfield, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mercy Hospital Springfield

from

Springfield, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Geisinger Medical Group

from

State College, PA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Mitchell Folbe MD PC

from

Sterling Heights, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Lakeview Hospital

from

Stillwater, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Stony Brook University Medical Center

from

Stony Brook, NY

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Missouri Baptist Outpatient Center-Sunset Hills

from

Sunset Hills, MO

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

MultiCare Tacoma General Hospital

from

Tacoma, WA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint Joseph's Hospital/Children's Hospital-Tampa

from

Tampa, FL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Carle Foundation Hospital

from

Urbana, IL

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

South Georgia Medical Center - Pearlman Cancer Ctr

from

Valdosta, GA

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Inspira Medical Center Vineland

from

Vineland, NJ

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Ridgeview Medical Center

from

Waconia, MN

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

University Hospitals Sharon Health Center

from

Wadsworth, OH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Saint John Macomb-Oakland Hospital

from

Warren, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

UW Cancer Center at ProHealth Care

from

Waukesha, WI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Henry Ford West Bloomfield Hospital

from

West Bloomfield, MI

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Methodist West Hospital

from

West Des Moines, IA

Myeloid Leukemia, Chronic, Chronic Phase Clinical Trial

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Status: Enrolling, Phase II
Updated: 12/31/1969

Univ of Massachusetts Med School

from

Worcester, MA

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

Status: Enrolling, Phase II
Updated: 12/31/1969

Oregon Health and Science University

from

Portland, OR

A Phase Ib/II Multicenter Open-label Study of BGB324 in Patients With AML or MDS

Status: Enrolling, Phase I, II
Updated: 5/16/2017

University of Iowa Hospitals and Clinics

from

Iowa City, IA

Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Status: Enrolling, Phase I
Updated: 12/31/1969

Ohio State University Comprehensive Cancer Center

from

Columbus, OH

University of California-Davis Comprehensive Cancer Ctr

Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Status: Enrolling, Phase I
Updated: 12/31/1969

from

Sacramento, CA

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Status: Enrolling, Phase I
Updated: 12/31/1969

OHSU Knight Cancer Institute

from

Portland, OR

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Status: Enrolling, Phase II
Updated: 12/31/1969

M D Anderson Cancer Center

from

Houston, TX

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancy's and Solid Tumors

Status: Enrolling, Phase I
Updated: 12/31/1969

University of Wisconsin Carbone Cancer Center

from

Madison, WI

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Status: Enrolling, Phase I
Updated: 12/31/1969

University of Texas M.D. Anderson Cancer Center

from

Houston, TX

Multiple Myeloma Clinical Trial

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Status: Enrolling, Phase I
Updated: 12/31/1969

Winship Cancer Institute at Emory University

from

Atlanta, GA

Multiple Myeloma Clinical Trial

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Status: Enrolling, Phase I
Updated: 12/31/1969

University of Pennsylvania:Abramson Cancer Center

from

Philadelphia, PA

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Nationwide Children's Hospital

from

Columbus, OH

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Inova Fairfax Hospital

from

Falls Church, VA

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Covenant Children's Hospital

from

Lubbock, TX

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

St. Jude Children's Research Hospital

from

Memphis, TN

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Children's Hospital of Philadelphia

from

Philadelphia, PA

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Naval Medical Center - San Diego

from

San Diego, CA

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

New York Medical College

from

Valhalla, NY

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Providence Alaska Medical Center

from

Anchorage, AK

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Children's Hospital Colorado

from

Aurora, CO

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Saint Luke's Mountain States Tumor Institute

from

Boise, ID

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Medical University of South Carolina

from

Charleston, SC

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

Golisano Children's Hospital of Southwest Florida

from

Fort Myers, FL

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Status: Enrolling, Phase III
Updated: 12/31/1969

BI-LO Charities Children's Cancer Center

from

Greenville, SC